Aurobindo Pharma Receives 11 Procedural US FDA Observations

announced the completion of a US FDA inspection at Unit-III of its subsidiary Eugia Pharma Specialities, a formulation facility in Pashamylaram, Telangana. The inspection spanned January 27 to February 6, 2026, resulting in 11 procedural observations noted on Form 483. The company plans to address these within regulatory timelines, affirming no impact on operations or financials. This follows a December 2025 inspection at another subsidiary site yielding three similar procedural notes, underscoring Aurobindo's ongoing compliance efforts. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.